Paclitaxel: Clinical Trials

1395 completed, 361 unknown, 328 recruiting, 317 terminated. 1639 Phase 2, 751 Phase 1, 678 Phase 3, 60 Not applicable, 30 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	1639	Completed 769, Unknown 214, Terminated 203, Recruiting 181, Active not recruiting 138, Not yet recruiting 69, Withdrawn 60, Suspended 3, Enrolling by invitation 2
Phase 1	751	Completed 424, Terminated 104, Recruiting 70, Unknown 57, Active not recruiting 50, Withdrawn 30, Not yet recruiting 10, Suspended 5, Enrolling by invitation 1
Phase 3	678	Completed 285, Recruiting 109, Unknown 95, Active not recruiting 89, Terminated 61, Not yet recruiting 21, Withdrawn 14, Suspended 4
Not applicable	60	Completed 21, Recruiting 11, Unknown 11, Not yet recruiting 6, Terminated 4, Active not recruiting 3, Withdrawn 3, Enrolling by invitation 1
Phase 4	30	Completed 12, Unknown 8, Recruiting 4, Terminated 3, Not yet recruiting 2, Withdrawn 1
Early Phase 1	14	Active not recruiting 3, Recruiting 3, Unknown 3, Completed 2, Enrolling by invitation 1, Terminated 1, Withdrawn 1

Follow Paclitaxel: new trials by email Literature Review of Paclitaxel trials Research Report on Paclitaxel

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8	Phase 1	Not yet recruiting	Northwestern University	18	2027-09-09	2026-10-20
HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer	Phase 2	Not yet recruiting	The University of The West Indies	750	2027-06-01	2026-09-22
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer AST-201, Paclitaxel, Carboplatin - Advanced Ovarian Cancer	Phase 2	Not yet recruiting	Aston Sci. Inc.	98	2027-06-01	2026-10-27
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck Cemiplimab, Fianlimab, Carboplatin - Squamous Cell Carcinoma	Phase 2	Not yet recruiting	University of Chicago	90	2027-02-07	2026-01-20
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer	Phase 2	Not yet recruiting	Massachusetts General Hospital	27	2027-02-01	2026-09-22
Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer	Phase 2	Not yet recruiting	Canadian Cancer Trials Group	160	2026-12-31	2026-10-27
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Cancer	Phase 3	Not yet recruiting	Asan Medical Center	172	2026-12-31	2026-10-29
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)	Phase 2	Not yet recruiting	Washington University School of Medicine	40	2026-12-31	2026-10-28
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Not yet recruiting	Exelixis	60	2026-12-15	2026-09-29
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer	Phase 2	Not yet recruiting	Bristol-Myers Squibb	80	2026-11-30	2026-10-13
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial	Phase 3	Not yet recruiting	GlaxoSmithKline	378	2026-11-12	2026-10-19
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung	Phase 1 / Phase 2	Suspended	National Cancer Institute (NCI)	60	2026-11-04	2026-10-30
Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin - Non-Small Cell Lung Cancer	Phase 2	Not yet recruiting	Medical University of South Carolina	38	2026-11-01	2026-07-22
Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung	Phase 2	Not yet recruiting	Yonsei University	69	2026-11-01	2026-09-04
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets Ivonescimab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer	Phase 2	Not yet recruiting	European Organisation for Research and Treatment of Cancer - EORTC	158	2026-11-01	2026-06-04
A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients HLX22, Trastuzumab, Capecitabine - HER2 + Breast Cancer	Phase 2	Not yet recruiting	Shanghai Henlius Biotech	90	2026-10-31	2026-09-17
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer. adebrelimab + SHR-A2009, paclitaxel or pemetrexed combined with carboplatin +adebrelimab, adebrelimab - Non-small Cell Lung Cancer	Phase 2	Not yet recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	660	2026-10-30	2026-10-07
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors	Phase 2	Not yet recruiting	Merck Sharp & Dohme LLC	480	2026-10-27	2026-10-08
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer HB0025 Injection, Paclitaxel injection, Carboplatin injection - First-line pMMR Endometrial Cancer	Phase 3	Recruiting	Shanghai Huaota Biopharmaceutical Co., Ltd.	333	2026-10-20	2026-10-29
A Prospective Trial of SFI Plus PD-1 Inhibitors and PBC in Resectable NSCLC (SFI-NSCLC) Shenqi Fuzheng Injection - Tear Disorder, Resectable Locally Advanced Non-Squamous NSCLC	Phase 4	Not yet recruiting	Anhui Provincial Cancer Hospital	30	2026-10-15	2026-10-29

Showing 20 of 2868. Sign in to see all of them.

Conditions studied

Breast Neoplasms (582)  ·  Carcinoma, Non-Small-Cell Lung (502)  ·  Ovarian Neoplasms (334)  ·  Lung Neoplasms (210)  ·  Fallopian Tube Neoplasms (156)  ·  Neoplasms (152)  ·  Stomach Neoplasms (130)  ·  Triple Negative Breast Neoplasms (129)  ·  Esophageal Neoplasms (128)  ·  Neoplasm Metastasis (124)  ·  Carcinoma, Ovarian Epithelial (115)  ·  Endometrial Neoplasms (98)  ·  Squamous Cell Carcinoma of Head and Neck (98)  ·  Uterine Cervical Neoplasms (81)  ·  Esophageal Squamous Cell Carcinoma (80)

Sponsors

National Cancer Institute (NCI) (159)  ·  M.D. Anderson Cancer Center (72)  ·  Merck Sharp & Dohme LLC (72)  ·  Hoffmann-La Roche (64)  ·  AstraZeneca (47)  ·  Bristol-Myers Squibb (45)  ·  Memorial Sloan Kettering Cancer Center (44)  ·  Eli Lilly and Company (38)  ·  Gynecologic Oncology Group (37)  ·  Alliance for Clinical Trials in Oncology (32)  ·  Fudan University (29)  ·  Genentech, Inc. (28)  ·  Novartis Pharmaceuticals (28)  ·  Eastern Cooperative Oncology Group (26)  ·  SWOG Cancer Research Network (26)

Countries

United States (1565)  ·  China (559)  ·  Spain (366)  ·  France (327)  ·  South Korea (322)  ·  Canada (301)  ·  Italy (301)  ·  Germany (291)  ·  United Kingdom (262)  ·  Japan (216)  ·  Belgium (211)  ·  Australia (209)  ·  Taiwan (192)  ·  Poland (188)  ·  Brazil (153)

Top investigators

Norman Wolmark, MD (9)  ·  Corey J. Langer, MD (8)  ·  Francesco Perrone, M.D., Ph.D. (8)  ·  Mariano Provencio, MD (8)

Results publications

PMID 37185961, PMID 34037241, PMID 32450725, PMID 35170751, PMID 38431043, PMID 40966692, PMID 21502559, PMID 21941283, PMID 22646630, PMID 25092775, PMID 30633128, PMID 31395089, PMID 35101941, PMID 37465924, PMID 16236738, PMID 16394300, PMID 18398152, PMID 19692680, PMID 22204724, PMID 22204725, PMID 22508812, PMID 22547591, PMID 23860537, PMID 24077916, PMID 24637997, PMID 24662947, PMID 24794243, PMID 25057165, PMID 25332249, PMID 25366678, PMID 25403584, PMID 26056183, PMID 26101239, PMID 26313683, PMID 26454620, PMID 28196905, PMID 28434660, PMID 29501363, PMID 29562804, PMID 30207593, PMID 30808774, PMID 30976202, PMID 31622131, PMID 32101663, PMID 32305010, PMID 32599071, PMID 33084020, PMID 33154826, PMID 33231285, PMID 33538338

NIH funding

2023 (57), U10CA180868 (53), U10CA027469 (36), 2014 (30), 2018 (30), 2016 (29), U10CA031946 (26), U10CA032102 (25), 2025 (23), 2017 (22), 2015 (20), 2009 (18), 2019 (18), U10CA180820 (16), U10CA021115 (14)